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Povidone iodineAbstract Introduction: Malignant pleural effusion is a serious problem for both patients and
physicians. Pleurodesis is considered the good solution for this dilemma. Chemical pleurodesis
was used to prevent ﬂuid reaccumulation and decrease patient suffering. This study was designed
to compare and evaluate the efﬁcacy and safety of three different sclerosing agents for preventing
recurrent malignant pleural effusion.
Materials and methods: Forty ﬁve patients with recurrent malignant pleural effusion were
enrolled in three groups; 15 patients in each one, and were subjected to pleurodesis using three
chemical agents.
Vincristine (2 mg), viscum (100 mg) and povidone–iodine (20 ml). All patients were subjected to
the thoracotomy tube for drainage of pleural ﬂuid, then sclerosing agents were instilled intrapleu-
rally via the tube.
Results: Vincristine, viscum and povidone–iodine resulted in complete pleurodesis in 53.3%,
73.3% and 73.3% respectively. Failed pleurodesis was higher in the vincristine group 26.7% but
in viscum and iodine groups were 13.3% and 20% respectively.
Pain was the most common complication 48.89% and reported in a higher ratio in the vincristine
group 66.67%, while in viscum and iodine groups it was 53.33% and 26.67% respectively.
There was no statistically signiﬁcant difference between the three groups regarding pleural ﬂuid
chemistry and duration of ICT.
Conclusion: According this study, povidone iodine is considered the ideal sclerosing agent for
pleurodesis in comparison to vincristine and viscum because of its high efﬁcacy, availability, cheap-
ness and least side effects.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).ai.com
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Pleural effusion is deﬁned as abnormal ﬂuid accumulation in
the pleural space, it is caused by many conditions, as: conges-
tive heart failure, pneumonia and malignancy [1]. Malignant
pleural effusion is a complication of many advanced malignan-
cies [2], which is usually secondary to lung and breast cancers,
but may be caused by any site of primary cancer as well as pri-
mary pleural malignancy [3]. Malignant pleural effusion is still
a common problem especially in patients with metastatic dis-
ease, they usually suffer from progressive dyspnea, dry cough
and chest pain in addition to reduced physical activity with
decreased quality of life [4]. Therapeutic possibilities for this
effusion are not always successful, additionally these patients
need to visit the hospital regularly for ﬂuid aspiration or even
stay hospitalized for several days.
Management of this ﬂuid is usually palliative, but is
undoubtedly needed to decrease patient complaints in addition
to improving patient quality of life [5].
Chemical pleurodesis is the recommended treatment for
these patients to prevent ﬂuid re-accumulation, and to reduce
patients suffering; either physically or psychologically [6].
There is no universal agreement on the most effective and
least harmful agents in inducing pleurodesis in malignant pleu-
ral effusion [7]. There are many agents available for chemical
pleurodesis, such as tetracycline derivatives, talc (insufﬂation
or slurry), bleomycin, mitoxantrone, nitrogen mustard, silver
nitrate, iodopovidone, dry killed Corynebacterium parvum [8].
Each of these agents has its own set of advantages and disad-
vantages, so the planned agent to be used must be selected judi-
ciously. The criteria for selection include agent’s effectiveness,
availability, ease of administration, cost and safety proﬁle [9].
Some physicians used cytotoxic drugs such as viscum
album L. (mistletoe) extract to induce pleurodesis in patients
with malignant effusion [10]. Vincristine also was used for
induction of pleurodesis in malignant pleural effusion [11].
Povidone–iodine was used mostly as an antiseptic agent, but
recently many studies used it as s sclerosing agent for pleurode-
sis because of its low-cost and availability [12].Aim of the study
The aim of this study is to compare and evaluate the efﬁcacy
and safety of viscum, vincristine and povidone–iodine in chem-
ical pleurodesis for recurrent malignant pleural effusion.
Materials and methods
This study was conducted prospectively on forty ﬁve patients
with recurrent malignant pleural effusion admitted either to
chest or cardiothoracic departments, Tanta University Hospi-
tal (Tanta city, Egypt) from March 2014 to May 2015. Malig-
nant pleural effusion was established using either positivity of
pleural ﬂuid cytology or thoracoscopic pleural biopsy.
Inclusion criteria
– Malignant pleural effusion (positive pleural ﬂuid for malig-
nant cells and/or positive pleural thoracoscopic biopsy for
malignant tissue).– Reaccumulation of malignant pleural effusion after ﬂuid
aspiration.
– Symptoms related to pleural ﬂuid reaccumulation as; dysp-
nea, cough and chest pain.
– Lung inﬂation after chest tube insertion and ﬂuid drainage.Exclusion criteria
– Patients with hypersensitivity to iodine.
– Incomplete lung inﬂation.
– Intrapleural chemotherapy or local radiotherapy to the
effusion side.
– Other comorbidity that can affect pleural effusion
reaccumulation.
– Encysted pleural effusion.
All patients were subjected to:
– Full history taking, general and local examination, chest X-
ray (CT in some cases), liver and kidney functions and
coagulation proﬁle.
– Chest tube was inserted under a complete aseptic technique
in the operating room under local anesthesia in 5th inter-
costal space midaxillary line, drainage of pleural effusion
was followed daily till it became less than 150 cc per 24 h
and chest X-ray was done to ensure complete pleural ﬂuid
evacuation with total inﬂation of the ipsilateral lung.
– Patients were subjected to pleurodesis after their random-
ization into 3 groups:
All patients received 15 ml of lidocaine (Xylocaine 2%,
Astra Zeneca) intrapleurally prior to sclerotherapy.
 Group A (vincristine group; 15 patients): intrapleural instil-
lation of 2 mg Vincristine Sulfate Injection (each vial of
10 ml contains 1 mg/ml Vincristine Sulfate) mixed with
100 ml of normal saline and injected via the chest tube
[13]. [Vincristine Sulfate Injection is manufactured by: Pﬁ-
zer (Perth) Pty Limited – Australia.]
 Group B (viscum group; 15 patients): intrapleural instilla-
tion of 5 ampules of Viscum Fraxini 2, (each ampoule
of 1 ml contains 20 mg mistletoe extract: equivalent to
10,000 ng Lectins) mixed with 100 ml of normal saline
and injected via the chest tube [14]. [Viscum Fraxini 2 is
manufactured by: ABNOBA Heilmittel GmbH – Germany.
Packed by: ATOS Pharma (Sekem Group) – Egypt.]
 Group C: (povidone–iodine group; 15 patients): intrapleural
instillation of 20 ml of 10% Betadine in 80 ml normal sal-
ine and injected via the chest tube [6]. [Betadine is manu-
factured by Nile Co. for Pharmaceuticals and Chemical
Industries, Cairo, Egypt; licensed by Mundi Pharma AG,
Basel, Switzerland.]
The tube was clamped for two hours, while that; the patient
was asked to change his position every 20 min to six directions
(supine, prone, sitting upright, right and left lateral decubitus
and lying low) to ensure the contact of sclerosing agents with
the whole pleural surfaces.
After two hours, the tube was unclamped. Follow up X-ray
was done daily until the amount of the drained ﬂuid became
less than 150 ml/day; the tube is removed.
Table 2 Distribution of patients regarding age.
Sex Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
X2 p
n % n % n %
Male 4 26.7 5 33.3 8 53.3 0.682 0.409
Female 11 73.3 10 66.7 7 46.7
Management of malignant pleural effusion and pleurodesis 437The patients were discharged and followed up after one and
two weeks using X-ray to evaluate the procedure success.
The efﬁcacy of pleurodesis was deﬁned in three levels of
response:
Complete: absence of pleural ﬂuid re-accumulation.
Partial: residual pleural ﬂuid or re-accumulation without
dyspnea, but did not require further drainage or remained
asymptomatic.
Failed: dyspnea with ﬂuid re-accumulation and additional
pleural procedures were necessary.Table 3 Distribution of patients regarding the side of pleural
effusion.
Side Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
X2 p
n % n % n %
Right 10 66.7 9 60 9 60 0.0127 0.987
Left 5 33.3 6 40 6 40Statistical analysis
For qualitative data; Chi-square test (X2) was used for com-
parison between the groups, for quantitative data; the mean
and standard deviation were calculated, then comparison
between them was done using a one way analysis of variance
(ANOVA).
A p value of less than 0.05 was considered statistically
signiﬁcant.
Results
A total of forty ﬁve patients with recurrent malignant pleural
effusion were enrolled during this study, of which 17
(37.78%) males and 28 (62.22%) females.
There was no statistically signiﬁcant difference between the
three groups regarding age (Table 1), sex (Table 2) and effu-
sion side (Table 3).
There was no statistically signiﬁcant difference between the
three groups as regards the chemical analysis of pleural effu-
sion (Table 4).
There was no statistically signiﬁcant difference between the
three groups regarding type of malignant tissue as regards
breast and bronchogenic carcinoma, but pleural mesothelioma
was found only in the iodine group, lymphoma was found in
the viscum group and secondary metastasis from colon, liver
ovary were found in the vincristine group (Table 5).
After pleurodesis; 30 cases (66.67%) developed complete
pleurodesis, while 6 cases (13.33%) developed partial pleu-
rodesis and only 9 (20%) cases had failed pleurodesis.
As regards the used chemical agents for pleurodesis; iodine
and viscum showed higher efﬁcacy in pleurodesis than vin-
cristine which showed the least efﬁcacy between the used
agents while viscum showed the lowest failure rate in compar-
ison to the other two agents (Table 6).
For all patients enrolled in the study, 22 (48.89%) devel-
oped pain, 15 (33.33%) complained of fever, 1 (2.22%) devel-
oped surgical emphysema and 1 (2.22%) the lung failed to
expand.Table 1 Distribution of patients regarding age.
Age (years) Vincristine group (n= 15) Viscum group (n
Range 43–70 30–75
Mean 57.4 57
SD 9.36 11.05There was no statistically signiﬁcant difference between the
three groups as regards complications of pleurodesis (Table 7).
For the duration of intercostal tube insertion and time of
removal after pleurodesis, there was no signiﬁcant difference
between the three groups (Table 8).
Discussion
Pleural effusion is a complication of many malignancies either
primary or secondary tumors affecting the pleura. It is valu-
able to prevent re-accumulation of pleural ﬂuid using
pleurodesis.
There are many methods for management of this recurrent
malignant effusion, chemical pleurodesis was the frequently
used one in most cases using sclerosing agents to induce sterile
adhesion of the pleura [7].
The present study is a trial for evaluation of the efﬁcacy and
safety of three sclerosing agents used in pleurodesis aiming to
have a step in reaching for the ideal sclerosing agent as regards
its price, availability, efﬁcacy and least complications.
Complete pleurodesis in the iodine group was 73.3%, while
partial success and failure rates were 6.7% and 20% respec-
tively, these results are related to results obtained by Godazan-
deh et al. [15] who reported 72.2% complete success using
povidone iodine for the induction of pleurodesis in malignant
effusion, while they reported partial success and failure rates of= 15) Iodine group (n= 15) F p
43–78
57.6 0.0127 0.987
11.06
Table 4 Chemical analysis of pleural effusion in the groups.
Eﬀusion chemistry Vincristine group (n= 15) Viscum group (n= 15) Iodine group (n= 15) F p
Mean SD Mean SD Mean SD
Glucose 84.93 11.62 82.87 15.67 91.87 24.19 1.036 0.364
Protein 4.25 0.53 4.08 0.47 3.85 0.75 1.723 0.191
LDH 546.80 114.87 505.33 177.44 504.93 227.88 0.270 0.765
Table 5 Distribution of patients regarding cancer type.
Cancer type Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
X2 p
n % n % n %
Breast 7 46.7 9 60 5 33.3 0.625 0.429
Bronch. cx 4 26.7 3 20 7 46.7 0.163 0.686
Mesothelioma 0 0 0 0 3 20
Lymphoma 0 0 2 13.3 0 0
Colon 1 6.7 0 0 0 0
Ovary 1 6.7 0 0 0 0
Liver 1 6.7 0 0 0 0
Unknown 1 6.7 1 6.7 0 0
Table 6 Distribution of patients regarding result of
pleurodesis.
Result of
pleurodesis
Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
X2 p
n % n % n %
Success 8 53.3 11 73.3 11 73.3 11.524 0.021
Partial
success
3 20 2 13.3 1 6.7 2 0.157
Failed
pleurodesis
4 26.7 2 13.3 3 20 3 0.223
Table 7 Distribution of patients regarding complications.
Complications
of pleurodesis
Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
X2 p
n % n % n %
Pain 10 66.67 8 53.33 4 26.67 1.6 0.206
Fever 7 46.67 6 75 2 13.33 0.6 0.439
Failed
expansion
0 0 0 0 1 6.67
Surgical
emphysema
0 0 0 0 1 6.67
Table 8 Distribution of patients regarding duration of ICT
after pleurodesis.
Days
of ICT
Vincristine
group
(n= 15)
Viscum
group
(n= 15)
Iodine
group
(n= 15)
F p
Mean 6.467 5.600 5.800 1.81 0.176
SD 1.187 1.352 1.373
438 R.M. El-Kolaly et al.19.4% and 8.4% respectively, this discrepancy in results may
be due to the small number of cases in the present study (15
patients) in comparison to Godazandeh’s study (36 patients).Agarwal and colleagues [16] studied 19 patients with pleural
effusions secondary to different pleural diseases and required
pleurodesis, they observed complete success with the absence
of re-accumulation of ﬂuid in 84.2% of cases.
In another study by Ibrahim et al. [17]; the success rate of
pleurodesis using povidone iodine was 66.7% which is less
than the percentage of success in the present study, while the
partial response to pleurodesis was 5.6% and this result is
nearly equal to the present study result.
Mohsen et al. [6] studied 22 patients with malignant pleural
effusion secondary to breast cancer, and subjected to pleurode-
sis using bedside povidone–iodine, they found that 17 patients
(85%) had complete response with no ﬂuid re-accumulation in
the post-procedure follow-up period, and failed pleurodesis
was found in three patients (15%).
Bakr et al. [18] compared four chemical agents for pleu-
rodesis in malignant pleural effusion, they reported 70% suc-
cess rate with 10% partial success and 20% failure rate in
the iodine group.
In a study designed to compare the effectiveness of intra-
pleural instillation of bleomycin with povidone–iodine for con-
trol of malignant pleural effusion, Alavi et al. [19] and his col-
leagues found that povidone iodine led to excellent and
effective pleurodesis in 75% of cases.
In another study; Shouman et al. [20] reported complete
success of pleurodesis in 66.7% of patients in the iodine group.
It is not known how iodine induces pleurodesis, but it may
be due to its low pH, which is 2.97, and it also has an oxidative
and cytotoxic effect leading to potent inﬂammatory reaction in
the pleural tissue and subsequently pleural symphysis [21].
In the present study, 15 patients were subjected to pleurodesis
using viscum, the success rate in this group was 73.3% while the
partial success and failure rate in this group were 13.3% in each.
Heinzerling et al. [22] studied the effect of intrapleural
instillation of viscum on the immune cells present in the effu-
sion liquid, their study showed a 72% success ratio which is
nearly equal to that of the recent study, and they also con-
cluded that intrapleural viscum instillation resulted in stimula-
tion of antitumour immunity via increasing the number of
immune cells in the ﬂuid.
Management of malignant pleural effusion and pleurodesis 439This explanation of viscum role was also highlighted by
Stumpf and his colleague [23], who concluded that; pleurodesis
by viscum in most patients was due to its sclerosing effect in
addition to stimulation of antitumour immunity in the ﬂuid,
so the local treatment not only aims to induce pleurodesis
but also to deal with the metastatic malignant cells themselves.
In a relative study by Elfeky and his colleagues [24] that
compared the efﬁcacy and safety of viscum and vincristine as
two anti neoplastic drugs used for chemical pleurodesis; the
success rate in the viscum group was 70%.
That success rate was higher than that obtained by Gaafar
et al. [25] who studied and evaluated the efﬁcacy of viscum as a
palliative treatment for malignant pleural effusions in compar-
ison with bleomycin, they concluded that clinical response and
complete pleurodesis was reported in 61.5% of the viscum
group.
In another study achieved also by Stumpf [26] about pleu-
rodesis, viscum instillation was used for the induction of pleu-
rodesis in 18 patients with recurrent malignant pleural
effusion, 11 (61.11%) showed complete remission (pleurode-
sis), 2 (11.11%) showed partial response and 4 (22.22%) failed
to respond.
In a recent study about effectiveness of viscum album in
pleurodesis; Elkasas et al. [27] found that; viscum album is
an effective agent for chemical pleurodesis in 52% of the stud-
ied patients.
In the present study, the vincristine group showed the least
success rate (53.3%) in comparison to the other two groups,
with partial success (20%) and failure ratio (26.7%) which is
the highest failure ratio among the three groups; these ratios
may be due to the few number of the studied patients which
necessitate to increase their number in another studies to revise
the effect of vincristine in pleurodesis.
Vidyasagar et al. [13] studied the usage of Vinca-Alkaloid
(vincristine) as a sclerosing agent for the palliative treatment
of malignant pleural effusions, and a high success rate (80%)
was noted while the failure rate was 6.67%.
The success ratio of the present study is also lower than that
obtained by Elfeky and his colleagues [24] who documented
63.33% success rate in pleurodesis using vincristine, and they
also showed a failure rate of 36.67% which is higher than that
of the present study, this may be due to the large number of
patients who were enrolled in their study (60 patients) in com-
parison to the present study (15 patients).
Cho et al. [28] reported complete pleurodesis with the vis-
cum in two patients with chylothorax.
The role of vincristine in pleurodesis needs to be further
investigated by other studies and also to be compared with
other sclerotic agents.
As regards post-pleurodesis complications in the present
study, pain was the biggest complaint of patients in all groups,
it was 10/15 (66.67%) in the vincristine group, 8/15 (53.33%)
in the viscum group and 4/15 (26.67%) in the iodine group.
Mohsen et al. [6] who compared talc and iodine as two scle-
rosing agents in malignant pleural effusion, found that chest
pain was not recorded in any patient in the iodine group.
In a relative study by Olivares-Torres et al. [12]; three
patients (5.8%) developed pain and were treated by opioids.
And also in a study by Neto et al. [21]; they reported that
16% of cases developed mild thoracic pain after iodopovidone
instillation.Shouman and his colleagues [20] compared four sclerosing
agents in pleurodesis, they reported chest pain in 13% of the
iodine group after its instillation in the pleural cavity.
In a study by, Godazandeh et al. [15], they found that;
35.9% of their patients developed chest pain after iodine
induced pleurodesis.
On the other hand Bakr et al. [18] reported in their study
that; 50% of the patients in the iodine group complained of
pain after pleurodesis. Also, Ibrahim et al. [17], found that
pain was recorded in 50% of cases subjected to pleurodesis
using povidone–iodine.
While Agarwal et al. [29] reported that all the studied cases
(100%) subjected to povidone–iodine pleurodesis experienced
chest pain.
This discrepancy in ratios may be due to different types and
doses of the analgesic that was used before pleurodesis, and
even some physicians did not use any analgesic in the begin-
ning of their procedures.
In a study by Elkasas et al. [27], they used viscum chemical
agent for pleurodesis in malignant pleural effusions, they
reported no pain in their studied patients.
Elfeky et al. [24] compared the efﬁcacy of vincristine and
viscum as sclerosing agents in malignant pleural effusion, they
reported pain in 23.33% in the vincristine group.
Stumpf [26] reported only 1% of patients that had pain as a
side effect after viscum pleurodesis.
When Elfeky et al. [24] used viscum as sclerosing agent in
malignant pleural effusion, they recorded pain in 18.33% of
patients, and these results were much lower than those
obtained in the present study.
As regards the other side effect of pleurodesis in the present
study, fever was found in 7 (46.67%) cases of the vincristine
group, 6 cases (75%) in the viscum group while it was found
in only two cases (13.33%) in the iodine group.
Ibrahim et al. [17] reported in their study; only four cases
(22.22%) developed fever after intrapleural instillation of
iodine and were treated by antipyretics. While Mohsen and
his colleagues [6] found in their study that; only one patient
(5%) in the iodine group developed fever after pleurodesis.
Shouman and his colleagues [20] found that 33% of
patients in iodine group developed fever after pleurodesis.
Bakr et al. [18] reported fever as a side effect of iodine pleu-
rodesis in 50% of patients.
In a study of Ruckdeschel et al. [30], they found that after
pleurodesis, fever presents only in one case (4%) of the viscum
group, and this result matched with that of Elkasas et al. [27]
who reported fever as a side effect in only one (4%) patient in
the Viscum group.
On the other hand, Stumpf [26] reported no fever in the vis-
cum group when he used it for pleurodesis.
In another study for comparing viscum and vincristine for
chemical pleurodesis by Elfeky et al. [24], they reported 15%
of patients developed fever in the viscum group and 20% of
patients developed fever in the vincristine group.
Vidyasagar and his colleagues [13] reported fever in one
patient (33%) when they used vincristine as a sclerosing agent
for malignant pleural effusions.
As previously mentioned that the limitation of the present
study is the small sample size in each group and another limi-
tation is not taking the pH of the pleural ﬂuid in consideration
because it can affect the success of pleurodesis as reported by
some authors [31].
440 R.M. El-Kolaly et al.There are not many studies evaluating the role of viscum as
a sclerosing agent and very few old studies about the sclerosing
effect of vincristine were published, so the results of these two
agents in the present study were not compared efﬁciently.
Conclusion
Povidone–iodine, viscum and vincristine are effective agents in
pleurodesis by different mechanisms, but vincristine is less in
efﬁcacy with more side effects than the other two agents.
Viscum and povidone–iodine are nearly equal in success
rate with fewer side effects, but according this study; povi-
done–iodine is considered the ideal sclerosing agent because
of its availability, low price, efﬁcacy and affordable and con-
trollable side effects in comparison to the other agents.
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